bromochloroacetic-acid and Leukemia--Myeloid--Acute

The interaction of pharmacologically active drugs with SC biochemical components is underestimated in pharmaceutical research. The aim of this research was to illustrate that some drugs intended for transdermal delivery could interact with the protein component of SC. Such interactions could be in favor of or opposition to their percutaneous absorption. IR microspectroscopy was used to delineate possible interaction of SC keratin with three losartan salts LOS-K, LOS-DEA and LOS-AML salts in addition to AML-BES salt. The results of PCA, combined with comparisons of average second derivative spectra of SC samples treated with these salts and the control SC, showed that LOS-DEA did not interact with SC, thus providing base line permeation of losartan. AML-BES, LOS-AML and LOS-K salts modified the conformational structure of keratin. The disorganization effect on the α-helical structure and induced formation of parallel β-sheets and random coils were in the order of AML-BES˃LOS-AML˃LOS-K. The order of the impact of treatments which resulted in increased formation of β-turns was AML-BES˃LOS-AML. The formation of antiparallel β-sheets was manifested by LOS-AML. Thus, the overall effect of these salts on the SC protein was AML-BES˃LOS-AML˃LOS-K. The impact of LOS-K was associated with improved permeation whereas the impact of LOS-AML was associated with hindered permeation of both losartan and amlodipine. There is a possibility that losartan and amlodipine when present in combination inside SC, their binding to the protein is enhanced leading to being retained within SC.

Topics: Amlodipine; Humans; Keratins; Leukemia, Myeloid, Acute; Losartan; Pharmaceutical Preparations; Salts; Skin

Here we describe a rare case of renal myeloid sarcoma, first discovered incidentally on routine urine analysis, which is one of the first of it's kind to be reported. We describe the vanishingly rare phenomenon of renal myeloid sarcoma presenting without haematological manifestation while also highlighting the often inevitable transformative nature of the disease. We also describe the unusual immunohistochemistry findings, in particular the cytokeratin expression, that is not usually typical of such cases. We briefly discuss use of PET-CT for the disease response monitoring. We summarize treatment that has included palbociclib, use of which was previously reported only in small series of patients with AML with KMT2A mutation.

Topics: Humans; Keratins; Kidney Neoplasms; Leukemia, Myeloid, Acute; Positron Emission Tomography Computed Tomography; Sarcoma, Myeloid; Soft Tissue Neoplasms

Topics: Aged; Hematopoietic Stem Cell Transplantation; Humans; Intermediate Filaments; Keratins; Leukemia, Myeloid, Acute; Male; Sarcoma, Myeloid; Stomach Neoplasms; Transplantation, Homologous

Myelosarcomas are, due to their rarity, a difficult differential diagnosis. Not infrequently, extensive immunohistochemical staining for characterization of the tumor is performed, if one does not directly think of myelosarcoma. In the present case, there was a positivity of the myeloid blasts for cytokeratin. This may complicate the discrimination of myelosarcoma from carcinoma, in particular small cell carcinoma, not only in the mediastinum, but also in the skin, e.g., Merkel cell carcinoma.

Topics: Adenocarcinoma; Biomarkers, Tumor; Cell Transformation, Neoplastic; Diagnosis, Differential; Female; Humans; Keratins; Leukemia, Myeloid, Acute; Lung Neoplasms; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Mediastinum; Middle Aged; Myeloid Cells; Neoplasms, Multiple Primary

Topics: Abdominal Pain; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Common Bile Duct Neoplasms; Female; Humans; Jaundice, Obstructive; Keratins; Leukemia, Myeloid, Acute; Middle Aged; Peroxidase; Proto-Oncogene Proteins c-kit; Pruritus; Sarcoma, Myeloid; Vimentin